الفهرس 
Introduction & Aim of the workOnly 14 pages are availabe for public view
 |  | from | 112 |  |  |
| | | from | 112 | | |
Abstract
SCH is becoming one of the most frequent diagnoses during daily practice of every physician, but the impact of such disease is yet to be uncovered. The link between SCH and CKD has been explored before, but no solid data has been established. The actual prevalence of SCH among CKD patients and the impact of this particular thyroid disease on CKD patients is a subject of many recent studies.
In this study we aimed at exploring the prevalence of SCH among CKD patients at MINIA University Hospital.
This cross-sectional study recruited patients from out-patient clinic of Nephrology unit at Nephrology and urology Minia University Hospital over a period of 6 month duration, 180 subjects were recruited 106 males (58.9%), 74 females (41.1%), from the same age group (18-60 years).
All included patients were subjected to the following:
I- Thorough Clinical history.
II- Careful Clinical examination.
III- Collection of any previous laboratory or radiological investigations.
IV- laboratory assessment:
FT3, FT4, TSH, and serum creatinine & blood urea levels, in addition to eGFR calculation.
The results of this study revealed that:
I- There is a high prevalence of SCH among CKD patients, out of 180 patients 48 patients (26.7%) had hormonal profile of SCH.
II- Age, eGFR, BMI and cause of CKD were important factors affecting the prevalence of SCH. However, there was no significant association between SCH and female gender among CKD patients opposed to general population.
III- SCH tended to be more prevalent among older patients the mean age of patients with SCH was (55.5) years compared to (48.85) years in Euthyroid patients (P-value was <0.0001).
IV- SCH tended to be more prevalent among more obese patients overt hypothyroid patients and patients with SCH tended to be more obese with mean BMI of (28.16) and (27.14) respectively compared to a mean BMI of (24.6) in subjects with normal thyroid functions (P-value was <0.0001).
V- SCH tended to be more prevalent among patients with more advanced CKD (more elevated renal chemistry, eGFR, and advanced stage of CKD). 26 patients (54.2%) of our CKD stage IV patients had SCH and 17 patients (35.4%) of our CKD stage IIIb patients had SCH, compared to a mere 5 patients with SCH in stage I, II and IIIa combined; on the other hand patients with SCH tended to have a more advanced CKD and a lower eGFR; so we can say that SCH and CKD are deeply inter-related.
VI- DM and hypertension were the leading causes of CKD in our sample, and they were related to higher prevalence of SCH. DM had the largest share of our SCH patients a striking 24 (50%) of patients with CKD caused by DM had SCH, in another 16 (33.3%) of our SCH patients hypertension was the cause of CKD (P-value was <0.0001).
VII- Patients with CKD caused by Obstructive uropathy, repeated urinary tract infection, congenital causes, lupus nephritis, GN or interstitial nephritis had much lesser prevalence of SCH.